FDA Orange Book · active-ingredient family
Amlodipine besylate; celecoxib
Amlodipine besylate; celecoxib is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:CONSENSI · NDA 210045
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CONSENSIRLD×3 | PURPLE BIOTECH | NDA 210045 | — | May 31, 2018 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10350171 | Jun 14, 2038 | in 12 yr 2 mo | Product |
Amlodipine besylate; celecoxib — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
